Inappropriate Doses of Intravenous Polymyxin B after Renal Adjustment Lead to Treatment Failure
DOI:
https://doi.org/10.1590/s2175-97902020000119036Keywords:
Polymyxin B. Sub-therapeutic dose. Renal impairment. Treatment failure.Abstract
Sub-therapeutic doses, shorter duration of therapy, female gender, bacteremia, and renal impairment were among independent predictors of polymyxin B treatment failure. In this study, we found an association between inappropriate doses of polymyxin B (<15000 or >25000 unit/kg/day) and renal impairment. Inappropriate doses of polymyxin B were significantly associated with CrCl 20-50 mL/ min (p = 0.021, ORadj 6.660, 95% CI 1.326, 33.453) and CrCl <20 mL/min (p = 0.001, ORadj 22.200, 95% CI 3.481, 141.592). By conducting sub-group analysis only using subjects with appropriate dosage, renal impairment was not associated with polymyxin B treatment failure, thus indicating that treatment failure was due to an inappropriate dose of polymyxin B, rather than renal impairment. In conclusion, renal impairment was not directly associated with treatment failure but was due to an inappropriate dosage of polymyxin B after renal adjustment.
Downloads
References
Azad MA, Finnin BA, Poudyal A, Davis K, Li J, Hill PA, Nation RL, Velkov T5, Li J. Polymyxin B Induces Apoptosis in Kidney Proximal Tubular Cells. Antimicrob Agents Chemother. 2013;57(9):4329-4335.
Deris ZZ. The multidrug-resistant gram-negative superbug threat requires intelligent use of the last weapon. Malays J Med Sci. 2015;22(5):1-6.
Dubrovskaya Y, Chen T-Y, Scipione MR, Esaian D, Phillips MS, Papadopoulos J, Mehta SA. Risk factors for treatment failure of polymyxin B monotherapy for carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother. 2013;57(11):5394-5397.
GlobalRPh. 2015. Polymyxin B (polymyxin b sulfate) injection from http://www.globalrph.com/polymyxin_b_dilution.htm#DOSAGE " (accessed 5th Nov 2015).
» http://www.globalrph.com/polymyxin_b_dilution.htm#DOSAGE
Ismail B, Shafei M., Harun A, Ali S, Omar M, Deris ZZ. Predictors of polymyxin B treatment failure in Gram-negative healthcare-associated infections among critically ill patients. J Microbiol Immunol Infect. 2018;51(6):763-769.
Kubin CJ, Ellman TM, Phadke V, Haynes LJ, Calfee DP, Yin MT. Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy. J Infect. 2012;65(1):80-87.
Kwa ALH, Abdelraouf K, Low JGH, Tam VH. Pharmacokinetics of polymyxin B in a patient with renal insufficiency: a case report. Clin Infect Dis. 2011;52(10): 8. 1280-1281.
Nation RL, Velkov T, Li J. Colistin and polymyxin B: peas in a pod, or chalk and cheese? Clin Infect Dis. 2014;59(1):88-94.
Sandri AM, Landersdorfer CB, Jacob J, Boniatti MM, Dalarosa MG, Falci DR, et.al. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: Implications for selection of dosage regimens. Clin Infect Dis. 2013a;57(4):524-531.
Sandri AM, Landersdorfer CB, Jacob J, Boniatti MM, Dalarosa MG, Falci DR, et al. Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis. J Antimicrob Chemother. 2013b;68(3):674-677.
Thamlikitkul V, Dubrovskaya Y, Manchandani P, Ngamprasertchai T, Boonyasiri A, Babic JT, et al. Dosing and pharmacokinetics of polymyxin B in patients with renal insufficiency. Antimicrob Agents Chemother. 2017;61(1):e01337-16.
Zavascki AP. Dose Adjustment of Polymyxins for Renal Insufficiency. Antimicrob Agents Chemother. 2011;55(10):4940.
Zavascki AP, Goldani LZ, Cao G, Superti SV, Lutz L, Barth AL et al. Pharmacokinetics of intravenous polymyxin B in critically ill patients. Clin Infect Dis. 2008;47(10):1298-1304.
Zavascki AP, Nation RL. Nephrotoxicity of Polymyxins: Is There Any Difference between Colistimethate and Polymyxin B? Antimicrob Agents Chemother. 2017;61(3):e02319-16.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on-line journal has open and free access.
